MedPath

Evaluation of oral Selenium Sulfide effect on treatment of Refractory Obsessive Compulsive Disorder in a Randomized Double Blind Placebo-Controlled Clinical Trial

Phase 3
Conditions
obsessive compulsive disorder.
Obsessive-compulsive disorder
Registration Number
IRCT20180212038699N1
Lead Sponsor
Ahvaz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Age between 18 to 62 years
Minimum score of Yale brown questionnaire should be 21
Obtaining written informed consent before entering into the study
use fluoxetine 20 mg once a day

Exclusion Criteria

Pregnancy
Internal diseases (diabetic patients , hypertension & ...)
Psychotic patients and mood disorders and neurology diseases
Thinking about suicide
Addiction to alcohol and narcotics
IQ below 80

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Obsession and compulsion score in Yale–Brown Obsessive Compulsive Scale (Y-BOCS). Timepoint: measurement yale brown questionnaire score in the began of first week and in the end of sixth week. Method of measurement: yale brown questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath